Substituted benzimidazole derivatives as angiotensin II -AT1 receptor antagonist: A review

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 14, 2010, Pages 1366-1384

  Vyas, V K ^a   Ghate, M ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

ACEIs; Ang II receptor blockers; Angiotensin II; AT1 receptor; AT2 receptor; Substituted benzimidazole derivatives

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ALISKIREN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; BENAZEPRIL; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CV 11174; CV 11194; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALKIREN; FOSINOPRIL; HETEROCYCLIC NITRO COMPOUND; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; PEPSTATIN; PIMOBENDAN; QUINAPRIL; REMIKIREN; RENIN INHIBITOR; SARALASIN; STATINE; TAK 536; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANKIREN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPERTENSION; MOLECULAR INTERACTION; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BENZIMIDAZOLES; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 78649879904     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710793564151     Document Type: Review

References (119)

1. Vallotton, M.B. The renin-angiotensin system. Trends Pharmacol. Sci., 1987, 8, 69-74.
2. Laragh, J. H.; Brenner, B.M. In: Hypertension: pathophysiology, diagnosis and management, Sealey, J.E.; Laragh, J.H. Raven Press, New York, 1990, pp. 1287-1317.
3. Dzau, V.J.; Pratt, R.E. In: Hand book of experimental cardiology, Haber, E.; Morgan, H.; Katz, A. Raven Press New York, 1986, D1631- D1661.
4. Zaid, A.; Winaver J.; Feuerste G.Z. The biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and reality. Biochem. Pharmacol., 2009, 78, 933-940.
5. Corvol, P. New Therapeutic Prospects of Renin-Angiotensin System Inhibition. Clin. Exp. Hypertens., 1989, A11, 463.
6. Gavras, H.; Brunner, H. R.; Turini, G. A.; Kershaw, G. R.; Tifft, C. P.; Cuttelod, S.; Gavras, I.; Vukovich, R. A.; McKinstry, D. N. Antihypertensive Effect of the Oral Angiotensin Converting- Enzyme Inhibitor Sq 14225 in Man. N. Engl. J. Med., 1978, 298, 991-995.
7. De Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; and Unger, T. The angiotensin II receptors. Pharmacol. Rev., 2000, 52(3), 415-472.
8. Laragh, J.H. Historical perspective on renin system blockade in the treatment of hypertension. Am. J. Hypertens., 1992, 5, 20X+8s.
9. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol., 1983, 2, 755-763.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med., 1991, 325, 293-302.
11. Case, D.B.; Atlas, S.A.; Marion, R.M.; Laragh, J.H. Long-term efficacy of captopril in renovascular and essential hypertension. Am. J. Cardiol., 1982, 49, 1440-1446.
12. The CONSENSUS Trial Study Group. Effect of enalapril on mortality and severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N. Engl. J. Med., 1987, 316, 1429-1435.
13. Timmermans, P.B.M.W.M.; Wong, P.C.; Chiu, A.T.;, Herblin, W.F. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol. Sci., 1991, 12, 55-62.
14. Timmermans, P.B.M.W.M.; Carini, D.J.; Chiu, A.T.; Duncia, J.V.; Price, W.A. Jr; Wells, G.J.; Wong, P.C., Wexler, R.R.; Johnson, A.L. Angiotensin II receptor antagonists: from discovery to antihypertensive drugs. Hypertension, 1991, 18, 136-142.
15. Wong, P.C.; Price, W.A. Jr; Chiu, A.T.; Duncia, J.V.; Carini, D.J.; Wexler, R.R.; Johnson, A.L.; Timmermans, P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 1990, 252, 719-725.
16. Wong, P.C.; Price, W.A. Jr; Chiu, A.T.; Duncia, J.V.; Carini, D.J.; Wexler, R.R.; Johnson, A.L.; Timmermans, P.B.M.W.M. In vivo pharmacology of DuP753. Am. J. Hypertens., 1991, 4, 288-3028.
17. Wong, P.C.; Price, W.A. Jr; Chiu, A.T.; Duncia, J.V.; Carini, D.J.; Wexler, R.R.; Johnson, A.L.; Timmermans, P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists. Antihypertehsive activity in rats of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 1990, 252, 726-732.
18. Tofovic, S.P.; Pong, A.S.; Jackson, E.K. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension, 1991, 18, 774-782.
19. Mizuno, K.; Niimura, S.; Tani, M.; Haga, H.; Gomibuchi, T.; Sanada, H.; Fukuchi S. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Eur. J. Pharmaco1., 1992, 215, 305-308.
20. Christen, Y.; Waeber, B.; Nussberger, J.; Lee, R.J.; Timmermans, P.B.M.W.M.; Brunner, H.R. Dose-response relationship following oral administration of DuP753 to normal humans. Am. J. Hypertens., 1991, 4, 3508-3539.
21. Morton, J.J.; Beattie, E.D.; MacPherson, F. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J. Vast. Res., 1992, 29, 264-269.
22. Abdelrahman, A.; Pang, C.C. Competitive antagonism of pressor responses of angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan. Can. J. Physiol. Pharmacol., 1992, 70, 716-719.
23. Christen, Y.; Waeber, B.; Nussberger, J.; Porchet, M.; Borland, R.M.; Lee, R.J.; Maggon, K.; Shum, L.; Timmermans, P.B.M.W.M.; Brunner, H.R. Oral administration of DuP 753. a suecific angiotensin II receptor antagonist, to normal volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation, 1991, 83, 1333-1342.
24. Brunner, H.R.; Christen, Y.; Munafo, A.; Lee, R.J.; Waeber, B.; Nussberger, J. Clinical experience with angiotensin II receptor antagonists. Am. J. Hypertens., 1992, 5, 243-269.
25. Hagino, T.; Abe, K.; Tsunoda, K.; Yoshinaga, K. Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK 954, in patients with essential hypertension. Nippon. Jinzo. Gakkai. Shi., 1992, 34, 133-140.
26. Tsunoda, K.; Abe, K.; Hagino, T.; Omata, K.; Misawa, S.; Imai, Y.; Yoshinaga, K. Hypotensive effect of losartan, a nonpeptide anaiotensin II receptor antagonist, in essential hypertension. Am. J. Hypertens., 1993, 1, 28-32.
27. Munafo, A.; Christen, Y.; Nussbereer, J.; Shum, L.Y.; Borland, R.M.; Lee, R.J.; Waeber, B.; Biollaz, J.; B;unner, H.R. Drug concentral tion response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin. Pharmacol. Ther., 1992, 51, 513-521.
28. Deschepper, C.F. Angiotensinogen: hormonal regulation and relative importance in the generation of angiotensin II. Kidney Int., 1994, 46, 1561-1563.
29. Hall, J.E. Historical perspective of the renin-angiotensin system. Mol. Biotechnol., 2003, 24, 27-39.
30. Gyurko, R.; Kimura, B.; Kurian, P.; Crews, F.T.; Phillips, M.I. Angiotensin II receptor subtypes play opposite roles regulating phosphatidylinositol hydrolysis in rat skin slices. Biochem. Biophys. Res. Commun., 1992, 186, 285-292.
31. Menard, J.; Bouhnik, J.;Clauser, E.; Richoux, J.P.; Corvol, P. Biochemistry and regulation of angiotensinogen. Clin. Exp. Hypertens., 1983, 445, 1005-1019.
32. Persson, P.B; Skalweit, A.; Thiele, B.J. Controlling the release and production of renin. Acta Physiol. Scand., 2004, 181, 375-381.
33. Morgan, L.; Broughton, P.F.; Kalsheker N. Angiotensinogen: molecular biology, biochemistry and physiology. Int. J. Biochem. Cell Biol., 1996, 28, 1211-1222.
34. Carey, R.M.; Siragy, H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev., 2003, 24, 261-271.
35. McConnaughey, M.M.; McConnaughey, J.S.; Ingenito, A.J. Practical considerations of the pharmacology of angiotensin receptor blockers. J. Clin. Pharmacol., 1999, 39, 547-59.
36. Hollenberg, N.K.; Fisher, N.D.; Price, D.A. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension, 1998, 32, 387-392.
37. Peach, M.J.; Dostal, D.E. The angiotensin II receptor and the actions of angiotensin II. J. Cardiovasc. Pharmacol., 1990, 16, S25-30.
38. Chiu, A.T.; Herblin, W.F.; McCall D.E.; Ardeck, R.J.; Carini, D.J.; Duncia, J.V.; Pease, L.J.; Wona, P.C.; Wexler, R.R.; Johnson, A.L.; Timmermans, P.B.M.W.M. Identification of angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun., 1989, 165, 196-203.
39. Herblin, W.F.; Chiu, A.T.; McCall, D.E.; Ardecky, R.J.; Carini, D.J.; Duncia, J.V.; Pease, L.J.; Wong, P.C.; Wexler, R.R.; Johnson, A.L.; Timmermans P.B.M.W.M. Angiotensin II receptor heterogeneity. Am. J. Hypertens., 1991, 4, 2099-3028.
40. Timmermans, P.B.M.W.M.; Chiu, A.T.; Herblin, D.M.; Wong, P.C.; Smith, R.D. Angiotensin II receptor subtypes. Am. J. Hypertens., 1992, 5, 406-410.
41. Bergsma, D.J.; Ellis, C.; Kumar, C.; Nuthulaganti, P.; Kersten, H.; Elshourbagy, N.; Griffin, E.; Stade, J.M.; Alyar, N. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem. Biophys. Res. Commun., 1992, 183, 989-995.
42. Sasamura, H.; Hein, L.; Krieger, J.E.; Pratt, R.E.; Kobika, B.K.; Dzau, V.J. Cloning, characterization and expression of two angiotensin receptor (AT-l) isoforms from the mouse genome. Biochem. Biophys. Res. Commun., 1992, 185, 253-259.
43. Ernsberger, P.; Zhou, J.; Damon, T.H.; Douglas, J.G. Angiotensin II receptor subtypes in cultured rat renal mesangial cells. Am. J. Physiol., 1992, 263, F411-416.
44. Leung, K.H.; Smith, R.D.; Timmermans, P.B.M.W.M.; Chiu, A.T. Regional distribution of the two subtypes of angiotensin II receptors in rat brain using selective nonpeptide antagonists. Neurosci. Lett., 1991, 123, 95-98.
45. Yamada, T.; Horiuchi, M.; Dzau, V.J. Angiotensin II type 2 receptor mediates programmed cell death. Proc. Natl. Acad. Sci. USA, 1996, 93, 156-160.
46. Yoshimura, Y.; Karube, M.; Aoki, H.; Oda, T.; Koyama, N.; Nagai, A.; Akimoto, Y.; Hirano, H.; Nakamura, Y. Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Endocrinology, 1996, 137, 1204-1211.
47. Steven, A.; Atlas, M.D. Role of angiotensin II in cardiovascular disease-therapeutic implications of more than a century of research. J. Manag. Care Pharm., 2007, 13, S9-S20.
48. Carey, R.M.; Siragy, H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev., 2003, 24, 261-271.
49. Gauquelin, G.; Garcia, R. Characterization of glomerular angiotensin II receptor subtypes. Receptor, 1992, 2, 207-212.
50. Stanton, A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs, 2003, 3, 389-394.
51. Edwards, R.M.; Stack, E.J.; Weidley, E.F.; Aiyar, N.; Keenan, R.M.; Hill, D.T.; Weinstock, J. Characterization of renal angiotensin II receptors using subtype selective antagonists. J. Pharmaco1. Exp. Ther., 1992, 260, 933-938.
52. Murphy, T.J.; Takeuchi, K.; Alexander, R.W. Molecular cloning of AT1 angiotensin receptors. Am. J. Hypertens., 1992, 5, 236-242.
53. Levy, B.I.; Benessiano, J.; Henrion, D.; Caputo, L.; Heymes, C.; Duriez, M.; Poitevin, P.; Samuel, J.L. J. Chronic blockade of AT2- subtype receptors prevents the effect of angiotensin II on the rat vascular structure. Clin. Invest., 1992, 98, 418-425.
54. Nakajima, M.; Hutchinson, H.G.; Fujinaga, M.; Hayashida, W.; Morishita, R.; Zhang, L.; Horiuchi, M.; Pratt, R.E.; Dzau, V.J. The angiotensin II type 2 AT2 receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. USA, 1995, 92, 10663-10667.
55. Buhler, F.R.; Laragh, J.H.; Baer, L.; Vaughan, E.D. Jr, Brunner, H.R. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N. Engl. J. Med., 1972, 287, 1209-1214.
56. Ondetti, M.A.; Rubin, B.; Cushman, D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science, 1977, 196, 441-444.
57. Tenenbaum, A.; Grossman, E.; Shemesh, J.F.; Isman, E.Z.N.; Osrati, I.; Motro, M. Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am. J. Hypertens., 2000, 13, 776-782.
58. Nussberger, J.; Cugno, M.; Amstutz, C.; Cicardi, M.; Pellacani, A.; Agostoni, A. Plasma bradykinin in angio-oedema. Lancet, 1998, 351, 1693-1697.
59. Wakerlin, G.E. Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation, 1953, 17, 653-657.
60. Deodar, S.D.; Haas, E.; Goldblatt, H. Production of antirenin to homologous renin and its eff ect on experimental renal hypertension. J. Exp. Med., 1964, 119, 425-431.
61. Michel, J.B.; Guettier, C.; Philippe, M.; Galen, F.X.; Corvol, P.; Menard, J. Active immunization against renin in normotensive marmoset. Proc. Natl. Acad.Sci. USA, 1987, 84, 4346-4350.
62. Gross, F.; Lazar, J.; Orth, H. Inhibition of the reninangiotensinogen reaction by pepstatin. Science, 1971, 175, 656-656.
63. Kleinert, H.D.; Rosenberg, S.H.; Baker, W.R.; Stein, H.H.; Klinghofer, V.; Barlow, J.; Spina, K.; Polakowski, J.; Kovar, P.; Cohen, J.; Denissen, J. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science, 1992, 257, 1940-1943.
64. Pool, J.L. Direct renin inhibition: focus on aliskiren. J. Manag. Care. Pharm., 2007, 13(8), S21-S33.
65. Skidgel, R.A. Erdos, E. In: The Renin-Angiotensin System, Robertson, J.I.S.; Nicholls, M.G., Ed.; Raven Press Ltd New York, 1993, pp. 10.1-10.10.
66. Sealey, J.E.; Laragh, J.H. Hypertension: Pathophysiology, Diagnosis, and Management, Laragh, J.H.; Brenner, B.M.; Ed.; Raven Press Ltd New York, 1990, pp. 1287-1317.
67. Zusman, R.M. Effects of converting-enzyme inhibitors on the reninangiotensin- aldosterone, bradykinin, and arachidonic acidprostaglandin systems: correlation of chemical structure and biologic activity. Am. J. Kidney Dis., 1987, 10, 13-23.
68. Mira, M.L.; Silva, M.M.; Manso, C.F. The scavenging of oxygen free radicals by angiotensin converting enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds. Ann. N. Y. Acad. Sci., 1994, 723, 439-441.
69. Wong, J.; Patel, R.A.; Kowey, P.R. The clinical use of angiotensinconverting enzyme inhibitors. Prog. Cardiovasc. Dis., 2004, 47, 116-130.
70. Brown, B.; Hall, A.S. Renin-angiotensin system modulation: the weight of evidence. Am. J. Hypertens., 2005, 18, 127S-133S.
71. Nancy, J.; Brown; Douglas, E. Angiotensin-Converting Enzyme Inhibitors. Circulation, 1998, 97, 1411-1420.
72. Ferrari, R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert. Rev. Cardiovasc. Ther., 2005, 3, 15-29.
73. Suzuki, H.; Kawaratani, T.; Shioya, H.; Uji, Y.; Saruta, T. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. Biopharm. Drug Dispos., 1993, 14, 41-50.
74. Todd, P.A.; Heel, R.C. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs, 1986, 31, 198-248.
75. Pals, D.T.; Masucci, F.E.; Sipos, F.; Denning, G.S. Jr. A specific competitive antagonist of the vascular action of angiotensin II. Circ. Res., 1971, 29, 664-672.
76. Gavras, H.; Brunner, H.R.; Vaughan, E.D. Jr; Laragh, J.H. Angiotensin- sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science, 1973, 180, 1369-1372
77. Case, D.B.; Wallace, J.M.; Laragh, J.H. Comparison between saralasin and converting enzyme inhibitor in hypertensive diseases. Kidney Int., 1979, 15, S107-S114.
78. Streeten, D.H.; Anderson, G.H.; Freiberg, J.M.; Dalakos, T.G. Use of angiotensin II antagonist'(saralasin) in'the recognition of "angiotensinogenic" hypertension. N. Engl. J. Med., 1975, 292, 657-662.
79. Timmermans, P.B.M.W.M.; Carini, D.J.; Chiu, A.T.; Duncia, J.V.; Price, W.A. Jr; Wells, G.J.; Wong, P.C.; Johnson, A.L.; Wexler, R.R. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am. J. Hypertens., 1991, 4, 275-819.
80. Furukawa, Y.; Kishimoto, S.; Nishikawa, K. Hypotensive imidazole derivatives. U.S. Patent 4,340,598, 1982.
81. Furukawa, Y.; Kishimoto, S.; Nishikawa, K. Hypotensive imidazole -5- acetic acid derivatives. U.S. Patent 4,355,040, 1982.
82. Chiu, A.T.; Carini, D.J.; Johnson, A.L.; Mc Call, D.E.; Price Jr., W.A.; Thoolen, M.J.M.C.; Wong, P.C.; Taber, R.L.; Timmermans, P.B.M.W.M. Nonpeptide angiotensin II (AII) receptor antagonists. II. Pharmacology of S-8308. Eur. J. Pharmacol., 1988, 157, 13-21.
83. Lew, M.J.; Ziogas, J.; Christopoulos, A. Dynamic mechanisms of nonclassical antagonism by competitive AT1 receptor antagonists. Sciences, 2000, 21, 376-381.
84. Wong, P.C.; Price Jr.; W.A.; Chiu, A.T.; Duncia, J.V.; Carini, D.J.; Wexler, R.R.; Johnson, A.L.; Timmermans, P.B.M.W.M. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonist. Hypertension, 1990, 15, 459-468.
85. Duncia, J.V.; Chiu,A.T.; Carini,D.J.; Gregory,G.B.; Johnson,A.L.; Price Jr.,W.A.; Wells,G.J.; Wong, P.C.; Calabrese, J.C.; Timmermans, P.B.M.W.M. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J. Med. Chem., 1990, 33, 1312-1329.
86. Moore, G.J. Designing peptide mimetics. Trends Pharmacol., 1994, 15, 124-129.
87. Bergsma, D. J.; Ellis, C.; Kumar, C.; Nuthulaganti, P.; Kersten, H.; Elshourbagy, N.; Griffin, E.; Stadel, J. M.; Aiyar, N. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem. Biophys. Res. Commun., 1992, 183, 989-995.
88. Underwood, D. J.; Strader, C. D.; Rivero, R.; Patchett, A. A.; Greenlee, W. J.; Prendergast, K. Structural model of antagonist and agonist binding to the angiotensin II AT1 subtype G protein coupled receptor. Chem. Biol., 1994, 1, 211-221.
89. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E. Price, W. A.; Snatella, J. B.; Wells, G. J. Wexler, R. R.; Wong, P. C.; Yoo, S. E.; Timmermans, P.B.M.W.M. nonpeptide Angiotensin II Receptor antagonist: the discovery of a series of N-{biphenyl methyl } Imidazole as Potent orally active Hypertensive. J. Med. Chem., 1991, 34, 2525-2547.
90. Kubo, K.; Yasuhisa, K.; Imamiya, E.; Yoshihiro, S.; Inada, Y.; Furukawa, Y.; Nishikawa, N. T. Nonpeptide angiotensin II receptor antagonist synthesis and biological activity of benzimidazolecarboxylic acids. J. Med. Chem., 1993, 36, 2182-2195.
91. Ries U.J.; Mihm, G.; Narr, B.; Hasselbach, K.M.; Wittneben, H.; Entzeroth, M.; Van Meel J.C.; Wienen W.; Hauel N.H. 6- Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structureactivity relationships. J. Med. Chem., 1993, 25, 4040-4051.
92. Sever, P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J. Hum. Hypertens, 1997, 2, S91-95.
93. Kubo, K.; Kohara, Y.; Yoshimura, Y.; Inada, Y.; Shibouta, Y.; Furukawa, Y.; Kato, T.; Nishikawa, K.; Naka, T. Nonpeptide angiotensin II receptor antagonists. synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J. Med Chem., 1993, 36, 2343-2349.
94. See, S.; Stirling, A.L. Candesartan cilexetil: an angiotensin IIreceptor blocker. Am. J. Health Syst. Pharm., 2000, 57, 739-746.
95. Wienen, W.; Hauel, N.; van Meel, J. C. A.; Nan, B.; Ria, U. J.; Entzeroth, M. Pharmacological characterization of the novel nonpeptide angiotensin I1 receptor antagonist BIBR 277. J. Pharmcol., 1993, 110, 245-252.
96. Bohm, M.; Lee, M.; Kreutz, R.; Kim, S.; Schinke, M.; Wagner, J.; Kaling, M.; Wienen, W.; Bader, M.; Ganten, D. The angiotensin antagonist BIBR-277 normalizes blood pressure and improves kidney damage in TGR (mREN2)27. F.A.S.E.B. J., 1993, 7, A246.
97. Yamagishi, S.; Takeuchi, M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med. Hypotheses, 2005, 64, 476-478.
98. Yamagishi S., Nakamura, K. Telmisartan, its potential therapeutic implications in cardiometabolic disorders. Recent Patents on Cardiovas. Drug Discov., 2006, 1, 79-83.
99. Benson, S.C.; Pershadsingh, H.A.; Ho, C.I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery M.A.; Kurtz, T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR- modulating activity. Hypertension, 2004, 43, 993-1002.
100. Thomas, A.P.; Allott, C.P.; Gibson, K.H.; Major, J.S.; Mesek, B.B.; Oldham, A.A.; Ratcliffe A.H.; Roberts, D.A.; Russell, S.T.; Thomason, D.A. New non peptide angiotensin II receptor antagonist 1. synthesis, biological properties and structure-activity relationships of 2-alkyl benzimidazole derivatives. J. Med. Chem., 1992, 35, 877-885.
101. Kubo, K.; Yoshiyuki, I.; Yasuhisa, K.; Yoshihiro, S.; Mami O.; Katsuhiko I.; Yoshiyasu, F.; Kohei, N.; Takehiko N. Nonpeptide angiotensin II receptor antagonist. synthesis and biological activity of benzimidazole. J. Med. Chem., 1997, 36, 1772-1784.
102. Kubo, K.; Kohara, Y.; Yoshimura, Y.; Inada, Y.; Shibouta, Y.; Furukawa, Y.; Kato, T.; Nishikawa, K.; Naka, T. Nonpeptide angiotensin II receptor antagonists. synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J. Med. Chem., 1993, 36, 2343-2349.
103. Kohara, Y.; Kubo, K.; Imamiya, E.; Inada Y.; Naka, T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J. Med. Chem., 1996, 39, 5228-5235.
104. Dorsch, D.; Mederski, W.W.K.R.; Beier, N.; Lues, I.; Minck, K.; Schelling P. (6-oxo-3-pyridazinyl)-benzimidazoles as potent angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 1994, 11, 1297-1302.
105. Gibson, K.H.; Wood, R.; Oldham, A.A.; Major, J.S. Major The synthesis of heterosubstituted benzimidazole derivatives with potent angiotensin II antagonist activity. Bioorg. Med. Chem. Lett., 1993, 3, 1019-1024.
106. Palkowitz, A. D.; Steinberg, M. I.; Zimmerman, K. M.; Thrasher, K. J.; Hauser, K. L.; Boyd D. B. Synthesis and Pharmacological Evaluation of A Novel Series of 5-aryl benzimidazole angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 1995, 5, 1015-1020.
107. Bali, A.; Bansal, Y.; Sugumaran, M.; Saggu, J.S.; Balakumar, P.; Kaur, G.; Bansal G.; Sharma, A.; Singh, M. Design, synthesis and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 3962-3965.
108. Xu J. Y.; Ran, Q.; Hua, W. Y.; Wu M. X.; Wang Q. J.; Zhang J. Design and synthesis of 2-alkylbenzimidazole derivatives as novel non-peptide angiotensin II AT1 receptor antagonists. Chin. Chem. Lett., 2007, 18, 251-254.
109. Xu, J. Y.; Zeng, Y.; Ran, Q.; Wei, Z.; Qian, Y. B.; Qiu, H. H.; Wang, J.; Hu,S.; Zhang J.; Tang, M.Y.; Huaa, W. Y.; Wua X. M. Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 2921-2926.
110. Shah, D.I.; Sharma, M.; Bansal, Y.; Bansal, G.; Singh M. Angiotensin II -AT1 receptor antagonists: Design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives Eur. J. Med. Chem., 2008, 43, 1808-1812.
111. Kaur, N.; Kaur, A.; Bansal, Y.; Shah, D.I.; Bansal, G.; Singh M. Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists. Bioorg. Med. Chem., 2008, 16, 10210-10215.
112. Guo, Xing-Zhou; Shi, Lin; Wang, Rui; Liu, Xiao-Xiao; Li, Bo-Gang; Lu, Xiao-Xia. Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring. Bioorg. Med. Chem., 2008, 16, 10301-10310.
113. Mizuno C.S.; Chittiboyina A.G.; Shah F.H.; Patny A.; Kurtz T.W.; Pershadsingh, H.A.; Speth R.C.; Karamyan V.T.; Carvalho P.B.; Avery M. A. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome. J. Med. Chem., 2010, 53, 1076-1085
114. Sharma, M.C.; Kohli, D.V.; Sharma, S. Synthesis and biological evaluation of some new benzimidazoles derivatives 4'-{5-amino-2- [2-substituted-phenylamino)-phenyl-methyl]-benzimidazol-1- ylmethyl}-biphenyl-2-carboxylic acid: nonpeptide angiotensin II receptor antagonists". Int. J. Drug Deliv., 2010, 2, 265-277.
115. Sharma, M.C.; Kohli, D.V.; Sharma, S. Benzimidazoles derivatives with (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) biphenyl-4- ylmethyl] 1H-benzoimidazol-2-yl}-phenyl)-(substituted-benzylidene)- amine with potential angiotensin II receptor antagonists as antihypertensive activity". Int. J. Drug Deliv., 2010, 2, 228-237.
116. Jat, R.K.; Jat, J.; Pathak D. P.; Synthesis of benzimidazole derivatives:as anti-hypertensive agents. E- J. Chem., 2006, 13, 278-285.
117. Jain A.; Chaturvedi S.C. QSAR modeling of some substituted benzimidazole as Angotensin II AT1 receptor antagonist. Med. Chem. Res., 2010, 19, 177-185.
118. Jain A.; Chaturvedi S.C. Rationalization of physicochemical property of some substituted benzimidazole bearing acidic heterocyclic towards angiotensin II antagonist: a QSAR approach. Asian J. Biochem., 2008, 3, 330-336
119. Jain A.; Chaturvedi S.C. QSAR study on 6-substituted benzimidazoles: an insight into the structural requirement for the angiotensin II AT1 receptor antagonist. Sci. Pharm. 2009, 77, 555-565.